Molecure (MOC) Q3 2026 earnings summary

Executive summary

• Focus remained on advancing OATD-01 Phase II KITE and OATD-02 Phase I, while reallocating resources from early-stage programs and developing AI drug-discovery tools.

• Positive IDMC recommendation followed KITE’s first interim review; management prioritized reaching 50 patients for the next analysis and pursuing partnering opportunities.

Financial highlights

• 9M 2026 operating revenue was PLN 2.69m vs PLN 3.81m YoY; operating costs were PLN 11.96m vs PLN 18.41m.

• 9M operating loss was PLN 9.27m vs PLN 14.60m; net loss was PLN 9.19m vs PLN 13.80m YoY.

• Operating cash outflow was PLN 9.96m vs PLN 16.48m; investing outflow was PLN 16.52m vs PLN 11.94m, and financing inflow was PLN 22.15m vs PLN 32.90m.

• Q3 operating costs fell PLN 2.0m YoY; 9M operating costs were down PLN 6.45m, attributed partly to restructuring and suspension of early programs.

Outlook and guidance

• The 2026–27 spending plan totals ~PLN 65m: ~PLN 39m for OATD-01/02 clinical programs, PLN 10m for discovery, preclinical work and AI, and PLN 16m for general, administrative and BD costs.

• Current plans assume KITE concludes after its second interim analysis, with final CSR in Q3 or Q4 2027; if re-estimation requires 96 patients, completion could extend into 2028.

• Additional funding of ~PLN 20m is needed through end-2027; projected need arises in Q1 2027, and efforts target securing funds by end-2026.

• KITE’s second interim results after 50 patients are expected before end-Q2 2027; the study’s blinded adaptive design allows sample-size adjustment.